Fidelity Investments’s Larimar Therapeutics LRMR Stock Holding History

Fidelity Investments’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$286K	Buy	63,570 +50,690	+394%	+$203K	﹤0.01%	3348
2025 Q4	$49.1K	Sell	12,880 -1,473	-10%	-$5.73K	﹤0.01%	4125
2025 Q3	$46.4K	Buy	14,353 +523	+4%	+$1.96K	﹤0.01%	4007
2025 Q2	$40K	Buy	13,830 +12,518	+954%	+$29K	﹤0.01%	3998
2025 Q1	$2.82K	Sell	1,312 -42,891	-97%	-$136K	﹤0.01%	4829
2024 Q4	$171K	Sell	44,203 -482,547	-92%	-$3.19M	﹤0.01%	3329
2024 Q3	$3.45M	Buy	526,750 +1,029	+0.2%	+$8.27K	﹤0.01%	2237
2024 Q2	$3.81M	Buy	525,721 +525,005	+73,325%	+$4.02M	﹤0.01%	2160
2024 Q1	$5.43K	Buy	716 +140	+24%	+$1.09K	﹤0.01%	4477
2023 Q4	$2.62K	Buy	576 +179	+45%	+$604	﹤0.01%	4596
2023 Q3	$1.57K	Buy	397 +185	+87%	+$700	﹤0.01%	4589
2023 Q2	$664	Buy	+212	New	+$865	﹤0.01%	4769
2019 Q3	–	Sell	-71,421	Closed	-$1.02M	–	4054
2019 Q2	$1.02M	Sell	71,421 -56,041	-44%	-$1.49M	﹤0.01%	2449
2019 Q1	$4.19M	Sell	127,462 -66,109	-34%	-$3.39M	﹤0.01%	2126
2018 Q4	$11.5M	Sell	193,571 -15,045	-7%	-$1.49M	﹤0.01%	1757
2018 Q3	$29.3M	Sell	208,616 -130,427	-38%	-$15.8M	﹤0.01%	1528
2018 Q2	$41.6M	Hold	339,043	–	–	﹤0.01%	1370
2018 Q1	$30.3M	Hold	339,043	–	–	﹤0.01%	1526
2017 Q4	$18.8M	Sell	339,043 -63	-0%	-$2.84K	﹤0.01%	1745
2017 Q3	$14.3M	Hold	339,106	–	–	﹤0.01%	1815
2017 Q2	$14.3M	Buy	339,106 +63	+0%	+$3.22K	﹤0.01%	1810
2017 Q1	$19M	Sell	339,043 -42	-0%	-$2.08K	﹤0.01%	1711
2016 Q4	$12.9M	Hold	339,085	–	–	﹤0.01%	1874
2016 Q3	$13.5M	Buy	339,085 +42	+0%	+$1.91K	﹤0.01%	1869
2016 Q2	$24.4M	Hold	339,043	–	–	﹤0.01%	1580
2016 Q1	$27.2M	Hold	339,043	–	–	﹤0.01%	1523
2015 Q4	$25.6M	Hold	339,043	–	–	﹤0.01%	1568
2015 Q3	$130M	Buy	339,043 +12,355	+4%	+$5.57M	0.02%	841
2015 Q2	$136M	Hold	326,688	–	–	0.02%	887
2015 Q1	$155M	Buy	326,688 +42,851	+15%	+$20.3M	0.02%	818
2014 Q4	$105M	Buy	283,837 +11,253	+4%	+$2.9M	0.01%	982
2014 Q3	$64.3M	Buy	+272,584	New	+$61.8M	0.01%	1181

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments's LRMR Position: Q1 2026 in Review

Fidelity Investments increased its Larimar Therapeutics (LRMR) stake by 394% in Q1 2026, buying an estimated $203K and bringing the position to 63,570 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #3348.

Fidelity Investments first reported a position in LRMR in Q3 2014 and has held it in 32 quarters since. The position peaked at $155M in Q1 2015. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

Fidelity Investments held 63,570 shares of Larimar Therapeutics worth $286K as of Q1 2026.
Fidelity Investments bought 50,690 Larimar Therapeutics shares in Q1 2026, an estimated $203K.
Larimar Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3348 holding.
Fidelity Investments first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 32 quarters since.
Fidelity Investments's Larimar Therapeutics position peaked at $155M in Q1 2015.
162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.